WO2025052417 - THERMOSTABLE COMPOSITION COMPRISING VESICULO VIRUS
National phase entry is expected:
Publication Number
WO/2025/052417
Publication Date
13.03.2025
International Application No.
PCT/IN2024/051606
International Filing Date
03.09.2024
Title **
[English]
THERMOSTABLE COMPOSITION COMPRISING VESICULO VIRUS
[French]
COMPOSITION THERMOSTABLE COMPRENANT UN VÉSICULOVIRUS
Applicants **
AURO VACCINES PRIVATE LIMITED
Inventors
SHARMA, Tarun
GUPTA, Pradeep Kumar
THADIKAMALA, Sathish
KHAN, Naseem Ahmed
MEYYAPPAN, Arumugam
Priority Data
202341059628
05.09.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2129 | |
| EPO | Filing, Examination, Granting | 12088 | |
| Japan | Filing, Examination, Granting | 2186 | |
| South Korea | Filing, Examination, Granting | 2204 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,347
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A stable composition comprising of genetically engineered vesiculovirus expressing a heterologous protein are disclosed. Said composition comprises pharmaceutically acceptable excipients selected from buffer, salt, and a globular protein individually and combination thereof. The said compositions are designed to be stored at widely available storage conditions for enhancing the stability profile. The stability profiles achieved by the present disclosure renders the said composition to be deployed globally at affordable costs.[French]
L'invention concerne une composition stable comprenant un vésiculovirus génétiquement modifié exprimant une protéine hétérologue. Ladite composition comprend des excipients pharmaceutiquement acceptables choisis parmi un tampon, un sel et une protéine globulaire individuellement et une combinaison de ceux-ci. Lesdites compositions sont conçues pour être stockées dans des conditions de stockage largement disponibles pour améliorer le profil de stabilité. Les profils de stabilité obtenus par la présente invention permettent de déployer ladite composition mondialement à des coûts abordables.